Treating advanced radioresistant differentiated thyroid cancer

被引：6

作者：

Bible, Keith C. ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

来源：

LANCET ONCOLOGY | 2012年 / 13卷 / 09期

关键词：

PHASE-II TRIAL; SORAFENIB;

D O I：

10.1016/S1470-2045(12)70342-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：854 / 855

页数：3

共 11 条

[1]

Al-Eid HS., CANC INCIDENCE REPOR

[2]

American Cancer Society, 2012, Cancer Facts and Figures 2012

[3] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study [J].

Bible, Keith C. ;

Suman, Vera J. ;

Molina, Julian R. ;

Smallridge, Robert C. ;

Maples, William J. ;

Menefee, Michael E. ;

Rubin, Joseph ;

Sideras, Kostandinos ;

Morris, John C., III ;

McIver, Bryan ;

Burton, Jill K. ;

Webster, Kevin P. ;

Bieber, Carolyn ;

Traynor, Anne M. ;

Flynn, Patrick J. ;

Goh, Boon Cher ;

Tang, Hui ;

Ivy, Susan Percy ;

Erlichman, Charles .

LANCET ONCOLOGY, 2010, 11 (10) :962-972

[4] Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation [J].

Carr, Laurie L. ;

Mankoff, David A. ;

Goulart, Bernardo H. ;

Eaton, Keith D. ;

Capell, Peter T. ;

Kell, Elizabeth M. ;

Bauman, Julie E. ;

Martins, Renato G. .

CLINICAL CANCER RESEARCH, 2010, 16 (21) :5260-5268

[5] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study [J].

Cohen, Ezra E. W. ;

Rosen, Lee S. ;

Vokes, Everett E. ;

Kies, Merrill S. ;

Forastiere, Arlene A. ;

Worden, Francis P. ;

Kane, Madeleine A. ;

Sherman, Eric ;

Kim, Sinil ;

Bycott, Paul ;

Tortorici, Michael ;

Shalinsky, David R. ;

Liau, Katherine F. ;

Cohen, Roger B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4708-4713

[6] Phase II trial of sorafenib in advanced thyroid cancer [J].

Gupta-Abramson, Vandana ;

Troxel, Andrea B. ;

Nellore, Anoma ;

Puttaswamy, Kanchan ;

Redlinger, Maryann ;

Ransone, Kathy ;

Mandel, Susan J. ;

Flaherty, Keith T. ;

Loevner, Laurie A. ;

O'Dwyer, Peter J. ;

Brose, Marcia S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4714-4719

[7] Phase II Trial of Sorafenib in Metastatic Thyroid Cancer [J].

Kloos, Richard T. ;

Ringel, Matthew D. ;

Knopp, Michael V. ;

Hall, Nathan C. ;

King, Mark ;

Stevens, Robert ;

Liang, Jiachao ;

Wakely, Paul E., Jr. ;

Vasko, Vasyl V. ;

Saji, Motoyasu ;

Rittenberry, Jennifer ;

Wei, Lai ;

Arbogast, Daria ;

Collamore, Minden ;

Wright, John J. ;

Grever, Michael ;

Shah, Manisha H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) :1675-1684

[8]

Leboulleux S, 2012, LANCET ONCOL

[9] Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors [J].

Schutz, Fabio A. B. ;

Je, Youjin ;

Richards, Christopher J. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :871-877

[10] Cancers with increasing incidence trends in the United States: 1999 through 2008 [J].

Simard, Edgar P. ;

Ward, Elizabeth M. ;

Siegel, Rebecca ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (02) :118-128

← 1 2 →